RU96119971A - Способ получения биологического клея, изготовленного из концентрированных коагулирующих факторов посредством "высаливания" - Google Patents
Способ получения биологического клея, изготовленного из концентрированных коагулирующих факторов посредством "высаливания"Info
- Publication number
- RU96119971A RU96119971A RU96119971/04A RU96119971A RU96119971A RU 96119971 A RU96119971 A RU 96119971A RU 96119971/04 A RU96119971/04 A RU 96119971/04A RU 96119971 A RU96119971 A RU 96119971A RU 96119971 A RU96119971 A RU 96119971A
- Authority
- RU
- Russia
- Prior art keywords
- carried out
- proteins
- solubilization
- histidine
- tris
- Prior art date
Links
- 239000003364 biologic glue Substances 0.000 title 1
- 230000001112 coagulant Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
- 239000012141 concentrate Substances 0.000 claims 4
- 239000002244 precipitate Substances 0.000 claims 4
- 238000005063 solubilization Methods 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 229960002885 Histidine Drugs 0.000 claims 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 3
- 239000007983 Tris buffer Substances 0.000 claims 3
- 238000001556 precipitation Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N Aminocaproic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 2
- 210000002381 Plasma Anatomy 0.000 claims 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 238000011026 diafiltration Methods 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 108010071289 Factor XIII Proteins 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 229940012952 Fibrinogen Drugs 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- STCOOQWBFONSKY-UHFFFAOYSA-N Tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 238000005202 decontamination Methods 0.000 claims 1
- 230000003588 decontaminative Effects 0.000 claims 1
- 239000003599 detergent Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229940012444 factor XIII Drugs 0.000 claims 1
- 230000037320 fibronectin Effects 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 235000011056 potassium acetate Nutrition 0.000 claims 1
- 238000005185 salting out Methods 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 238000011146 sterile filtration Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 239000011778 trisodium citrate Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Claims (14)
1. Способ приготовления белкового концентрата, коагулируемого тромбином и содержащего в основном фибриноген, эндогенный фактор ХIII и фибронектин, характеризуется тем, что он предусматривает следующие стадии: а) первое осаждение белков цельной плазмы добавлением соли в достаточном количестве для достижения высаливания указанных белков и рН 7,5-8,5, причем осаждение проводят при 0-4oС в присутствии минимальной концентрации 50 мМ амино-6-гексановой кислоты, b) первая солюбилизация осажденных белков в присутствии L-гистидина до конечной концентрации 0,2-0,3 г на грамм белков, с) стадия дезактивации вирусов в растворе растворителя-детергента; d) второе осаждение той же самой солью, что и в стадии а) при той же температуре в присутствии той же самой концентрации амино-6-гексановой кислоты, е) промывание осадка слегка подкисленной чистой водой, f) вторая солюбилизация осадка в присутствии L-гистидина, как в стадии b), g) добавление 50% сахарозы по отношению к количеству белков, h) стерильное фильтрование, i) распределение аликвот стерильно профильтрованного концентрата в стерильные флаконы, и j ) лиофилизация.
2. Способ по п. 1, отличающийся тем, что указанная соль представляет собой ацетат натрия или калия.
3. Способ по п. 1, отличающийся тем, что первую и вторую стадии осаждения проводят в течение периода времени по меньшей мере 30 мин.
4. Способ по п. 1, отличающийся тем, что стадию е) проводят при 2oС с водой, охлажденной до 2oС.
5. Способ по п. 1, отличающийся тем, что стадии а), d) и е) проводят при комнатной температуре в течение по меньшей мере 30 мин.
6. Способ по п. 1, отличающийся тем, что после стадии е) следуют растворение осадка в слегка основной чистой воде и диализ или диафильтрование.
7. Способ по п. 1, отличающийся тем, что слегка подкисленная чистая вода является раствором Трис-НСl (0,1% с рН 4,5-5,0).
8. Способ по п. 6, отличающийся тем, что слегка основная чистая вода, используемая для растворения осадка перед диализом или диафильтрованием, является раствором 0,5% Трис рН 7,3.
9. Способ по п. 1, отличающийся тем, что первую солюбилизацию проводят в 1% Трис и 1,6% цитрате натрия рН 7,30 для доведения концентрации белка до 20-22 мг/мл перед добавлением L-гистидина.
10. Способ по п. 1, отличающийся тем, что вторую солюбилизацию проводят в 0,5% Трис рН 7,30 для доведения концентрации белка до 30-35 мг/мл перед добавлением L-гистидина.
11. Способ по п. 1, отличающийся тем, что дезактивацию вирусов выполняют при 28oС в течение 6 ч при непрерывном перемешивании в растворе, состоящем из 10 мг/мл растворенных белков, 1% Твин 80® и 0,3% Три-н-бутилфосфата.
12. Способ по п. 1, отличающийся тем, что лиофилизированный концентрат растворяется в воде менее, чем за 5 мин, при ручном перемешивании.
13. Способ по п. 12, отличающийся тем, что растворенный концентрат стабилен при температуре 4-20oС в течение по меньшей мере 24 ч.
14. Способ по п. 1, отличающийся тем, что плазма имеет человеческое или животное происхождение.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/021,302 US5395923A (en) | 1993-02-23 | 1993-02-23 | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
PCT/CA1994/000105 WO1995023167A1 (en) | 1993-02-23 | 1994-02-28 | Process for the obtention of a biological adhesive comprising fibrinogen, factor xiii and fibronectin |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96119971A true RU96119971A (ru) | 1998-11-20 |
RU2130946C1 RU2130946C1 (ru) | 1999-05-27 |
Family
ID=25683079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96119971A RU2130946C1 (ru) | 1993-02-23 | 1994-02-28 | Способ получения биологического клея, изготовленного из концентрированных коагулирующих факторов посредством "высаливания" |
Country Status (12)
Country | Link |
---|---|
US (1) | US5395923A (ru) |
EP (1) | EP0748337B1 (ru) |
JP (1) | JP3492694B2 (ru) |
AT (1) | ATE181738T1 (ru) |
AU (1) | AU678439B2 (ru) |
CA (1) | CA2113660C (ru) |
DE (1) | DE69419324T2 (ru) |
DK (1) | DK0748337T3 (ru) |
ES (1) | ES2135564T3 (ru) |
NO (1) | NO317699B1 (ru) |
RU (1) | RU2130946C1 (ru) |
WO (1) | WO1995023167A1 (ru) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197325B1 (en) | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
SE9301582D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Purification of plasma proteins |
US5585007A (en) * | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
DE69629010T2 (de) * | 1995-01-16 | 2004-04-15 | Baxter International Inc., Deerfield | Selbsttragende flächengebilde aus vernetztem fibrin zur hemmung von postoperativen adhäsionen |
JPH08333277A (ja) * | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | ヒト血液凝固第xiii因子の安定化された水性液製剤 |
WO1998002098A1 (en) | 1996-07-12 | 1998-01-22 | Baxter International Inc. | A fibrin delivery device and method for forming fibrin on a surface |
US8003705B2 (en) * | 1996-09-23 | 2011-08-23 | Incept Llc | Biocompatible hydrogels made with small molecule precursors |
AU4648697A (en) * | 1996-09-23 | 1998-04-14 | Chandrashekar Pathak | Methods and devices for preparing protein concentrates |
US6132598A (en) * | 1997-01-08 | 2000-10-17 | Bristol-Myers Squibb Company | Centrifuge apparatus with temperature control means |
IL130728A (en) * | 1997-01-08 | 2002-11-10 | Bristol Myers Squibb Co | Centrifuge apparatus with temperature control means |
CA2288143C (en) | 1997-04-28 | 2012-08-21 | Eli Lilly And Company | Activated protein c formulations |
US6630137B1 (en) * | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
US5900270A (en) * | 1997-09-22 | 1999-05-04 | Cobe Laboratories, Inc. | Technique for testing and coating a microporous membrane |
US5981254A (en) * | 1997-10-30 | 1999-11-09 | Haemacure Corporation | Process for producing thrombin from plasma |
US6503527B1 (en) * | 1997-11-17 | 2003-01-07 | Haemacure Corporation | Fibrin sealants or adhesives comprising a hyaluronic acid derivative material |
BE1012536A3 (fr) | 1998-11-04 | 2000-12-05 | Baxter Int | Element muni d'une couche de fibrine sa preparation et son utilisation. |
AU2707500A (en) | 1998-12-04 | 2000-06-26 | Incept Llc | Biocompatible crosslinked polymers |
US6310036B1 (en) | 1999-01-09 | 2001-10-30 | Last Chance Tissue Adhesives Corporation | High strength, Bio-compatible tissue adhesive and methods for treating vigorously bleeding surfaces |
CA2362513C (en) * | 1999-02-12 | 2011-04-26 | Baxter Aktiengesellschaft | A method for producing a preparation based on fibrinogen and fibronectin as well as protein compositions obtainable according to this method |
JP4771594B2 (ja) * | 1999-02-12 | 2011-09-14 | バクスター アクチェンゲゼルシャフト | フィブリノーゲンおよびフィブロネクチンをベースとする製剤を生成するための方法ならびにこの方法により入手可能なタンパク質組成物 |
US7654998B1 (en) | 1999-08-23 | 2010-02-02 | Aeris Therapeutics, Inc. | Tissue volume reduction |
US6610043B1 (en) | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
ES2327208T3 (es) | 1999-12-23 | 2009-10-27 | Csl Limited | Separacion de fibrinogeno de proteasas de plasma. |
US7204981B2 (en) * | 2000-03-28 | 2007-04-17 | Eli Lilly And Company | Methods of treating diseases with activated protein C |
AU2001262939A1 (en) | 2000-05-24 | 2001-12-03 | Eli Lilly And Company | Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states |
US6648911B1 (en) | 2000-11-20 | 2003-11-18 | Avantec Vascular Corporation | Method and device for the treatment of vulnerable tissue site |
WO2003071986A2 (en) * | 2002-02-22 | 2003-09-04 | Control Delivery Systems, Inc. | Method for treating otic disorders |
AU2003213146A1 (en) * | 2002-03-08 | 2003-09-22 | Eli Lilly And Company | Activated protein c formulations |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US7374678B2 (en) * | 2002-05-24 | 2008-05-20 | Biomet Biologics, Inc. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
AU2003249642A1 (en) * | 2002-05-24 | 2003-12-12 | Biomet Manufacturing Corp. | Apparatus and method for separating and concentrating fluids containing multiple components |
US20060278588A1 (en) | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
GB0216001D0 (en) | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
US7135027B2 (en) * | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
US9358318B2 (en) | 2004-10-20 | 2016-06-07 | Ethicon, Inc. | Method of making a reinforced absorbable multilayered hemostatic wound dressing |
US20060258995A1 (en) * | 2004-10-20 | 2006-11-16 | Pendharkar Sanyog M | Method for making a reinforced absorbable multilayered fabric for use in medical devices |
PL1809342T3 (pl) * | 2004-10-20 | 2015-12-31 | Ethicon Inc | Wchłanialny hemostat |
US7866485B2 (en) | 2005-02-07 | 2011-01-11 | Hanuman, Llc | Apparatus and method for preparing platelet rich plasma and concentrates thereof |
WO2006086201A2 (en) | 2005-02-07 | 2006-08-17 | Hanuman Llc | Platelet rich plasma concentrate apparatus and method |
ES2426941T3 (es) * | 2005-02-07 | 2013-10-25 | Hanuman Llc | Aparato y procedimiento de concentrados de plasma rico en plaquetas |
CN1911440A (zh) * | 2005-08-08 | 2007-02-14 | 上海莱士血制品有限公司 | 一种用于形成纤维蛋白膜的试剂盒及其应用 |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US8430813B2 (en) * | 2006-05-26 | 2013-04-30 | Depuy Spine, Inc. | Illuminated surgical access system including a surgical access device and integrated light emitter |
US20080187568A1 (en) * | 2007-02-06 | 2008-08-07 | Sawhney Amarpreet S | Polymerization with precipitation of proteins for elution in physiological solution |
US20090227689A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US20090227981A1 (en) * | 2007-03-05 | 2009-09-10 | Bennett Steven L | Low-Swelling Biocompatible Hydrogels |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
EP2146794B1 (en) | 2007-04-12 | 2016-10-19 | Biomet Biologics, LLC | Buoy suspension fractionation system |
US8067028B2 (en) * | 2007-08-13 | 2011-11-29 | Confluent Surgical Inc. | Drug delivery device |
EP2567692B1 (en) | 2008-02-27 | 2016-04-06 | Biomet Biologics, LLC | Use of a device for obtaining interleukin-1 receptor antagonist rich solutions |
EP2254991B1 (en) * | 2008-02-29 | 2018-08-22 | Biomet Manufacturing, LLC | A system and process for separating a material |
US8012077B2 (en) * | 2008-05-23 | 2011-09-06 | Biomet Biologics, Llc | Blood separating device |
AU2010213612B2 (en) | 2009-02-12 | 2015-04-30 | Incept, Llc | Drug delivery through hydrogel plugs |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8313954B2 (en) * | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
RU2561676C1 (ru) * | 2014-04-07 | 2015-08-27 | Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации | Способ получения клеящей массы |
US9932388B2 (en) | 2014-11-13 | 2018-04-03 | Hemarus Therapeutics Limited | Chromatographic process for producing high purity fibrinogen and thrombin |
US9713810B2 (en) | 2015-03-30 | 2017-07-25 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
US9757721B2 (en) | 2015-05-11 | 2017-09-12 | Biomet Biologics, Llc | Cell washing plunger using centrifugal force |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2826533A (en) * | 1954-03-15 | 1958-03-11 | Cutter Lab | Stable fibrinogen solutions and method for producing same |
JPS5598196A (en) * | 1979-01-16 | 1980-07-25 | Meito Sangyo Kk | Fractionation of fibrinogen or its constituents and their use |
AT359652B (de) * | 1979-02-15 | 1980-11-25 | Immuno Ag | Verfahren zur herstellung eines gewebekleb- stoffes |
AT390001B (de) * | 1984-09-28 | 1990-03-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
DE3622642A1 (de) * | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
US4876241A (en) * | 1987-05-22 | 1989-10-24 | Armour Pharmaceutical Company | Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants |
FR2618784B1 (fr) * | 1987-07-30 | 1990-04-06 | Lille Transfusion Sanguine | Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
US5030215A (en) * | 1990-01-03 | 1991-07-09 | Cryolife, Inc. | Preparation of fibrinogen/factor XIII precipitate |
WO1992013495A1 (en) * | 1991-02-07 | 1992-08-20 | Fibratek, Inc. | Fibrinogen based adhesive |
EP0534178B1 (en) * | 1991-09-27 | 2001-04-18 | Omrix Biopharmaceuticals S.A. | Improved tissue glue prepared by using cryoprecipitate |
US5290918A (en) * | 1993-02-23 | 1994-03-01 | Haemacure Biotech Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation |
-
1993
- 1993-02-23 US US08/021,302 patent/US5395923A/en not_active Expired - Lifetime
-
1994
- 1994-01-18 CA CA002113660A patent/CA2113660C/en not_active Expired - Fee Related
- 1994-02-28 ES ES94908221T patent/ES2135564T3/es not_active Expired - Lifetime
- 1994-02-28 DE DE69419324T patent/DE69419324T2/de not_active Expired - Lifetime
- 1994-02-28 RU RU96119971A patent/RU2130946C1/ru active
- 1994-02-28 JP JP52203595A patent/JP3492694B2/ja not_active Expired - Fee Related
- 1994-02-28 WO PCT/CA1994/000105 patent/WO1995023167A1/en active IP Right Grant
- 1994-02-28 DK DK94908221T patent/DK0748337T3/da active
- 1994-02-28 EP EP94908221A patent/EP0748337B1/en not_active Expired - Lifetime
- 1994-02-28 AU AU61515/94A patent/AU678439B2/en not_active Ceased
- 1994-02-28 AT AT94908221T patent/ATE181738T1/de not_active IP Right Cessation
-
1996
- 1996-08-28 NO NO19963602A patent/NO317699B1/no not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU96119971A (ru) | Способ получения биологического клея, изготовленного из концентрированных коагулирующих факторов посредством "высаливания" | |
US5395923A (en) | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" | |
US5290918A (en) | Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation | |
CA1126652A (en) | Antithrombin preparation and process for the production thereof | |
USRE29698E (en) | Stabilization of AHF using heparin | |
US5099003A (en) | Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii | |
US6541518B2 (en) | Enhanced production of safe plasma preparations | |
AU590546B2 (en) | Purification of blood coagulation factor viii by precipitation | |
ES2281104T3 (es) | Proceso para separar el inhibidor de alfa-1-proteinasa de una pasta de fraccion cohn iv-1 + iv-4. | |
AU2003244850B2 (en) | Processes for the preparation of fibrinogen | |
US4379085A (en) | Heat stabilization of plasma proteins | |
EP0148843B1 (en) | A concentrate of the antihemophilic factor viii and a process for producing it | |
FI81363B (fi) | Foerfarande foer pastoerisering av preparat av blodkoaguleringsfaktorerna ii, vii, ix och x. | |
EP0292003B1 (en) | Stabilzation of biological and pharmaceutical products during inactivation of viral and bacterial contaminants | |
JPH06505494A (ja) | Ix因子の調製 | |
JP2001500867A (ja) | 血漿タンパク質含有薬剤の製造方法 | |
US4822872A (en) | Method of purifying factor VIII | |
CN109071596B (zh) | 用于纯化纤维蛋白原的方法 | |
US5811279A (en) | Method for activating prothrombin with polyethylene glycol | |
FI96918B (fi) | Koostumus veriplasman stabiloimiseksi pastöroinnin aikana | |
Ratnoff | A. The Physiology of Blood Coagulation | |
DK175644B1 (da) | Fremgangsmåde til stabilisering af biologiske og farmaceutiske midler under inaktivering af virale og bakterielle kontaminanter | |
Wickerhauser | METHODS FOR PREPARATION OF CLINICAL FACTOR VIII CONCENTRATES | |
JPH06311883A (ja) | プラスミノゲンの製造方法 |